Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

Zanubrutinib capsules will be self-administered orally by participants at a starting dose of 160 mg twice a day (BID) or 320 mg once a day (QD)\* at the beginning of Cycle 2 of Pola-R-CHP therapy.

Participants will receive Methotrexate as per standard of care (SOC).

Participants will receive Polatuzumab Vedotin as per standard of care (SOC).

Participants will receive Rituximab as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.

Participants will receive Cyclophosphamide as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.

Participants will receive Doxorubicin as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.

Participants will receive Prednisone as per standard of care (SOC), as part of combination standard of care Pola-R-CHP therapy.